COMP <GO>
ZTS vs ABBV // FREE CASH FLOW YIELD
Zoetis Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ZTS 7
— ABBV 7
▲ FREE CASH FLOW YIELD LEADER: ZTS
LAST: $79.72 (+1.17%) • MKT CAP: $32.56B
fcf-yield
7.01%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZTS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZTS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.80% | 70.20% | +1.60 | ZTS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 25.70% | 29.00% | -3.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 10.3x | 33.3x | -23.00 | ZTS | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 7.01% | 3.47% | +3.54 | ZTS | /fcf-yield <GO> |
| Operating Margin | 34.40% | 24.60% | +9.80 | ZTS | /operating-margins <GO> |
| Net Profit Margin | 28.20% | 6.90% | +21.30 | ZTS | /net-margins <GO> |
| Revenue Growth (YoY) | 2.30% | 8.60% | -6.30 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.53 | 5.33 | -0.80 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.40% | -0.50 | ZTS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.4 | 72.8 | -12.34 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.15 | -0.16 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.3x | 113.1x | -101.80 | ZTS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $32.56B | $513.86B | -$481.30B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZTS REV | ABBV REV | ZTS GROSS % | ABBV GROSS % | ZTS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.47B | $61.16B | 71.8% | 70.2% | $2.28B | $17.82B |
| FY 2024 | $9.26B | $56.33B | 70.6% | 70.0% | $2.30B | $17.83B |
| FY 2023 | $8.54B | $54.32B | 44.0% | 44.0% | $1.97B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZTS // BETA 0.99
ABBV // BETA 1.15